UPDATE: Sterne Agee Initiates Coverage on AmerisourceBergen on Dominant Market Share

In a report published Thursday, Sterne Agee analyst Greg T. Bolan initiated coverage on

with a Buy rating and $80.00 price target. In the report, Sterne Agee noted, “With specialty drugs expected to capture an increasingly large footprint within the drug spend funnel, we believe ABC's dominant share within the specialty distribution channel will enable the company to achieve revenue growth and margins superior to those of its peers. Initiate with a Buy rating and $80 price target.” AmerisourceBergen Corp. closed on Wednesday at $61.49.